XML 64 R34.htm IDEA: XBRL DOCUMENT v3.25.3
ACQUISITIONS (Tables)
 12 Months Ended
Aug. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Business Combination, Recognized Asset Acquired and Liability Assumed The following table summarizes the allocation of the final purchase price for Immunetrics:
(in thousands)
Base merger consideration$12,000 
Fair value of earnout4,100 
Cash on hand1,247 
Adjustment to purchase price for closing indebtedness(122)
Net working capital adjustment(377)
D&O tail insurance(7)
Bonus compensation to Immunetrics staff(1,586)
Total purchase price15,255 
Fair value of identifiable assets acquired:
Cash1,132 
Accounts receivable511 
Security deposit12 
ROU asset227 
Deferred tax assets799 
Trade names1,800 
Customer relationships3,780 
Developed Tech1,080 
Non-competes30 
9,371 
Fair value of liabilities assumed:
Lease liability227 
Selling shareholders' D&O tail insurance responsibility7 
Deferred revenue60 
294 
Fair value of identifiable assets acquired and liabilities assumed9,077 
Goodwill$6,178 
The following table summarizes the allocation of the final purchase price for Pro-ficiency:
(in thousands)
Estimated fair value as previously reported (a)
Measurement Period AdjustmentsFair Value as adjusted
Base merger consideration$100,000 $— $100,000 
Net working capital adjustment(85)— (85)
Excess cash adjustment1,731 227 1,958 
Adjustment to purchase price for closing indebtedness(1,484)— (1,484)
Total purchase price100,162 227 100,389 
Fair value of identifiable assets acquired:
Cash2,513 — 2,513 
Accounts receivable2,064 — 2,064 
Prepaids and other current assets1,807 — 1,807 
ROU asset212 — 212 
Trade names8,400 — 8,400 
Customer relationships2,310 — 2,310 
Developed technology16,630 — 16,630 
Non-competes70 — 70 
Other non-current assets17 — 17 
34,023 — 34,023 
Fair value of liabilities assumed:— 
Accounts payable935 — 935 
Payroll and other current liabilities2,302 — 2,302 
Deferred revenue1,456 — 1,456 
Lease liability212 — 212 
Deferred tax liabilities4,811 (956)3,855 
Other liabilities1,124 — 1,124 
10,840 (956)9,884 
Fair value of identifiable assets acquired and liabilities assumed23,183 24,139 
Goodwill$76,979 $76,250 

(a) As previously reported in the Company's Annual Report on Form 10-K for the year ended August 31, 2024.
Schedule of Business Combination, Intangible Asset, Acquired, Finite-Lived and Indefinite-Lived
The following table summarizes intellectual property as of August 31, 2025:
(in thousands)Amortization
Period		Acquisition
Value		Accumulated
Amortization		ImpairmentNet Book
Value
Developed technologies–DILIsym acquisition
Straight line 9 years
$2,850 $2,610 $— $240 
Intellectual rights of Entelos Holding Company
Straight line 10 years
50 36 — 14 
Developed technologies–Lixoft acquisition
Straight line 16 years
8,010 2,670 — 5,340 
Developed technologies–Immunetrics acquisition
Straight line 5 years
1,080 477 — 603 
Developed technologies–Pro-ficiency acquisition
Straight line 5 years
16,630 3,228 13,402 — 
$28,620 $9,021 $13,402 $6,197 
In connection with the identified triggering event as of May 31, 2025, the Company performed, prior to the goodwill impairment test, a quantitative assessment of its long-lived assets and concluded that its long-lived assets were impaired at certain reporting units. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Developed technologies related to the Pro-ficiency acquisition were determined to be impaired. Such charges of $13.4 million are recorded in impairments on the Consolidated Statements of Operations and Comprehensive (Loss) Income.
The following table summarizes intellectual property as of August 31, 2024:
(in thousands)Amortization
Period		Acquisition
Value		Accumulated
Amortization		Net Book
Value
Developed technologies–DILIsym acquisition
Straight line 9 years
$2,850 $2,294 $556 
Intellectual rights of Entelos Holding Company
Straight line 10 years
50 30 20 
Developed technologies–Lixoft acquisition
Straight line 16 years
8,010 2,173 5,837 
Developed technologies–Immunetrics acquisition
Straight line 5 years
1,080 261 819 
Developed technologies–Pro-ficiency acquisition
Straight line 5 years
16,630 732 15,898 
$28,620 $5,490 $23,130 
The following table presents the details of intangible assets acquired.
(in thousands)Estimated useful lifeAmount
Indefinite-lived:
Trade namesIndefinite$1,800 
Definite-lived:
Customer relationships9 years3,780 
Developed technologies5 years1,080 
Covenants not to compete2 years30 
Total definite-lived intangible assets4,890 
Total intangible assets$6,690 
The following table presents the details of intangible assets acquired.
Estimated useful lifeAmount
Indefinite-lived:
Trade namesIndefinite$8,400 
Definite-lived:
Customer relationships10 years2,310 
Developed technologies5 years16,630 
Non-competes3 years70 
Total definite-lived intangible assets19,010 
Total intangible assets$27,410 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The estimated future amortization of finite-lived intangible assets for the next five years is as follows:
(in thousands)Amount
Years ending August 31,
2026$3,580 
2027$3,580 
2028$3,580 
2029$3,557 
2030$3,557 
Schedule of Business Combination, Pro Forma Information
(Pro forma)
2024 *		(Pro forma)
2023
(in thousands)(unaudited)(unaudited)
Revenue$83,243 $76,892 
Net (loss) income$7,790 $4,547 
* Balances include actual results from acquisition date of June 16, 2023 through August 31, 2023 for Immunetrics and from acquisition date of June 11, 2024 through August 31, 2024 for Pro-ficiency business.